Elevation Oncology (ELEV) to Release Quarterly Earnings on Thursday

Elevation Oncology (NASDAQ:ELEV) will likely be announcing its Q1 2025 earnings results before the market opens on Thursday, May 1st. Analysts expect Elevation Oncology to post earnings of ($0.20) per share for the quarter.

Elevation Oncology (NASDAQ:ELEV) last released its earnings results on Thursday, March 6th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.04. On average, analysts expect Elevation Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Elevation Oncology Stock Up 1.8 %

Shares of ELEV opened at $0.38 on Thursday. The company has a quick ratio of 17.77, a current ratio of 17.77 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $22.43 million, a price-to-earnings ratio of -0.46 and a beta of 1.65. The stock’s 50-day moving average price is $0.41 and its 200-day moving average price is $0.55. Elevation Oncology has a 52 week low of $0.22 and a 52 week high of $4.48.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. William Blair reaffirmed an “outperform” rating and set a $5.00 price target on shares of Elevation Oncology in a research report on Friday, March 7th. HC Wainwright dropped their target price on Elevation Oncology from $6.00 to $1.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Citizens Jmp downgraded Elevation Oncology from an “outperform” rating to a “market perform” rating in a research report on Friday, March 21st. Piper Sandler lowered Elevation Oncology from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $10.00 to $0.70 in a research note on Friday, March 21st. Finally, Leerink Partnrs downgraded Elevation Oncology from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 20th. Seven investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $3.39.

Hedge Funds Weigh In On Elevation Oncology

An institutional investor recently raised its position in Elevation Oncology stock. Bank of America Corp DE increased its stake in shares of Elevation Oncology, Inc. (NASDAQ:ELEV) by 42.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,839 shares of the company’s stock after purchasing an additional 16,962 shares during the period. Bank of America Corp DE owned approximately 0.10% of Elevation Oncology worth $32,000 as of its most recent SEC filing. 83.70% of the stock is owned by institutional investors.

About Elevation Oncology

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.